---
figid: PMC3573758__nihms371252f2
figlink: /pmc/articles/PMC3573758/figure/F2/
number: Figure 2
caption: Crosslinking of FcεRI-bound IgE with antigen induces aggregation of two or
  more FcεRI molecules and activates the protein tyrosine kinases LYN and FYN. LYN,
  in turn, phosphorylates the immunoreceptor tyrosine-based activation motifs (ITAMs)
  in FcεRI and activates the protein tyrosine kinase SYK (after SYK has bound to an
  ITAM). FYN phosphorylates the adaptor GAB2, activating the phosphatidylinositol-3-OH
  kinase (PI(3)K) pathway. LYN and SYK phosphorylate many adaptor molecules (such
  as LAT, not shown) and enzymes, thereby regulating the activation of the RAS–MAPK
  (mitogen-activated protein kinase), phospholipase C-γ (PLC-γ) and PI(3)K pathways,
  as well as other pathways. (LYN also can negatively regulate FYN activity.) The
  RAS–MAPK pathway — a protein-kinase cascade that involves RAS, RAF, MEK and ERK
  — activates transcription factors (thereby regulating the synthesis of protein mediators)
  and activates PLA2, which participates in arachidonic acid metabolism (thereby regulating
  the production of lipid-derived mediators). PLC-γ activation regulates calcium (Ca2+)
  responses, by generating inositol-1,4,5-trisphosphate (InsP3), and protein kinase
  C (PKC) activation, by generating diacylglycerol (DAG). The PI(3)K product phosphatidylinositol-3,4,5-trisphosphate
  (PtdIns(3,4,5)P3) is an important lipid mediator that regulates the formation of
  other lipid mediators, such as DAG and sphingosine 1-phosphate (S1P), and the activity
  of various enzymes, such as Bruton’s tyrosine kinase (BTK) and AKT. FcεRI can be
  induced to co-aggregate with FcγRIIB (a low-affinity receptor for IgG), for example
  when IgE and IgG1 are bound to the same antigen. This process inhibits FcεRI signalling
  events, and therefore mast-cell activation and product secretion, through the LYN-mediated
  phosphorylation of the FcγRIIB ITIM (immunoreceptor tyrosine-based inhibitory motif)
  and the recruitment of the inositol phosphatase SHIP1 (which catalyses the hydrolysis
  of PtdIns(3,4,5)P3 to PtdIns(3,4)P2) (not shown). Some arrows do not indicate direct
  interactions or targets. NF-κB, nuclear factor-κB; SPHK1, sphingosine kinase 1.
pmcid: PMC3573758
papertitle: The development of allergic inflammation.
reftext: Stephen J. Galli, et al. Nature. ;454(7203):445-454.
pmc_ranked_result_index: '103043'
pathway_score: 0.9519732
filename: nihms371252f2.jpg
figtitle: Development of allergic inflammation
year: ''
organisms: Homo sapiens
ndex: 96d62d2b-deef-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3573758__nihms371252f2.html
  '@type': Dataset
  description: Crosslinking of FcεRI-bound IgE with antigen induces aggregation of
    two or more FcεRI molecules and activates the protein tyrosine kinases LYN and
    FYN. LYN, in turn, phosphorylates the immunoreceptor tyrosine-based activation
    motifs (ITAMs) in FcεRI and activates the protein tyrosine kinase SYK (after SYK
    has bound to an ITAM). FYN phosphorylates the adaptor GAB2, activating the phosphatidylinositol-3-OH
    kinase (PI(3)K) pathway. LYN and SYK phosphorylate many adaptor molecules (such
    as LAT, not shown) and enzymes, thereby regulating the activation of the RAS–MAPK
    (mitogen-activated protein kinase), phospholipase C-γ (PLC-γ) and PI(3)K pathways,
    as well as other pathways. (LYN also can negatively regulate FYN activity.) The
    RAS–MAPK pathway — a protein-kinase cascade that involves RAS, RAF, MEK and ERK
    — activates transcription factors (thereby regulating the synthesis of protein
    mediators) and activates PLA2, which participates in arachidonic acid metabolism
    (thereby regulating the production of lipid-derived mediators). PLC-γ activation
    regulates calcium (Ca2+) responses, by generating inositol-1,4,5-trisphosphate
    (InsP3), and protein kinase C (PKC) activation, by generating diacylglycerol (DAG).
    The PI(3)K product phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3)
    is an important lipid mediator that regulates the formation of other lipid mediators,
    such as DAG and sphingosine 1-phosphate (S1P), and the activity of various enzymes,
    such as Bruton’s tyrosine kinase (BTK) and AKT. FcεRI can be induced to co-aggregate
    with FcγRIIB (a low-affinity receptor for IgG), for example when IgE and IgG1
    are bound to the same antigen. This process inhibits FcεRI signalling events,
    and therefore mast-cell activation and product secretion, through the LYN-mediated
    phosphorylation of the FcγRIIB ITIM (immunoreceptor tyrosine-based inhibitory
    motif) and the recruitment of the inositol phosphatase SHIP1 (which catalyses
    the hydrolysis of PtdIns(3,4,5)P3 to PtdIns(3,4)P2) (not shown). Some arrows do
    not indicate direct interactions or targets. NF-κB, nuclear factor-κB; SPHK1,
    sphingosine kinase 1.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PLA2G7
  - PLA2G12B
  - PLA2G6
  - PLA2G2A
  - PLA2G4C
  - PLA2G2F
  - PLA2G10
  - PLA2G4A
  - PLA2G12A
  - PLA2G2D
  - PLA2G5
  - PRKCI
  - PRKCQ
  - PF4
  - CXCL6
  - PLD1
  - PLD2
  - AKT1
  - CXCL11
  - PRKCH
  - AKT3
  - PLA2G3
  - PLA2G1B
  - CXCL8
  - CXCL2
  - GAB2
  - CXCL9
  - PPBP
  - PRKCG
  - FCGRT
  - MAP2K2
  - AKT2
  - PRKCZ
  - PLD4
  - PLA2G2C
  - CXCL3
  - CXCL1
  - PLD3
  - PRKD3
  - LYN
  - PRKCB
  - KRAS
  - MAP2K1
  - PRKCE
  - ARAF
  - PLD6
  - PLA2G4D
  - PLA2G2E
  - CXCL13
  - PLD5
  - PIK3R3
  - MAPK3
  - PRKCA
  - FYN
  - NFKB1
  - PRKCD
  - CXCL12
  - NRAS
  - PIK3CG
  - BTK
  - PIK3CB
  - PIK3CA
  - CXCL5
  - MAPK1
  - RAF1
  - SYK
  - PIK3R6
  - CXCL10
  - PIK3CD
  - SPHK1
  - PIK3R4
  - INPP5D
  - CXCL14
  - HRAS
  - PIK3R5
  - BRAF
  - amines
  - Prostaglandins
  - Sphingosine
  - Leukotrienes
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: PLA2
  symbol: PLA2
  source: bioentities_symbol
  hgnc_symbol: PLA2G7
  entrez: '7941'
- word: PLA2
  symbol: PLA2
  source: bioentities_symbol
  hgnc_symbol: PLA2G12B
  entrez: '84647'
- word: PLA2
  symbol: PLA2
  source: bioentities_symbol
  hgnc_symbol: PLA2G6
  entrez: '8398'
- word: PLA2
  symbol: PLA2
  source: bioentities_symbol
  hgnc_symbol: PLA2G2A
  entrez: '5320'
- word: PLA2
  symbol: PLA2
  source: bioentities_symbol
  hgnc_symbol: PLA2G4C
  entrez: '8605'
- word: PLA2
  symbol: PLA2
  source: bioentities_symbol
  hgnc_symbol: PLA2G2F
  entrez: '64600'
- word: PLA2
  symbol: PLA2
  source: bioentities_symbol
  hgnc_symbol: PLA2G10
  entrez: '8399'
- word: PLA2
  symbol: PLA2
  source: bioentities_symbol
  hgnc_symbol: PLA2G4A
  entrez: '5321'
- word: PLA2
  symbol: PLA2
  source: bioentities_symbol
  hgnc_symbol: PLA2G12A
  entrez: '81579'
- word: PLA2
  symbol: PLA2
  source: bioentities_symbol
  hgnc_symbol: PLA2G2D
  entrez: '26279'
- word: PLA2
  symbol: PLA2
  source: bioentities_symbol
  hgnc_symbol: PLA2G5
  entrez: '5322'
- word: PKC)
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCI
  entrez: '5584'
- word: PKC)
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCQ
  entrez: '5588'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: PF4
  entrez: '5196'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL6
  entrez: '6372'
- word: PLD
  symbol: PLD
  source: bioentities_symbol
  hgnc_symbol: PLD1
  entrez: '5337'
- word: PLD
  symbol: PLD
  source: bioentities_symbol
  hgnc_symbol: PLD2
  entrez: '5338'
- word: AKT)
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL11
  entrez: '6373'
- word: PKC)
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCH
  entrez: '5583'
- word: AKT)
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PLA2
  symbol: PLA2
  source: bioentities_symbol
  hgnc_symbol: PLA2G3
  entrez: '50487'
- word: PLA2
  symbol: PLA2
  source: bioentities_symbol
  hgnc_symbol: PLA2G1B
  entrez: '5319'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL8
  entrez: '3576'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL2
  entrez: '2920'
- word: GAB2
  symbol: GAB2
  source: hgnc_symbol
  hgnc_symbol: GAB2
  entrez: '9846'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL9
  entrez: '4283'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: PPBP
  entrez: '5473'
- word: PKC)
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCG
  entrez: '5582'
- word: a-Chain
  symbol: alpha-chain
  source: hgnc_alias_symbol
  hgnc_symbol: FCGRT
  entrez: '2217'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: AKT)
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PKC)
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCZ
  entrez: '5590'
- word: PLD
  symbol: PLD
  source: bioentities_symbol
  hgnc_symbol: PLD4
  entrez: '122618'
- word: PLA2
  symbol: PLA2
  source: bioentities_symbol
  hgnc_symbol: PLA2G2C
  entrez: '391013'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL3
  entrez: '2921'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL1
  entrez: '2919'
- word: PLD
  symbol: PLD
  source: bioentities_symbol
  hgnc_symbol: PLD3
  entrez: '23646'
- word: PKC)
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKD3
  entrez: '23683'
- word: LYN
  symbol: LYN
  source: hgnc_symbol
  hgnc_symbol: LYN
  entrez: '4067'
- word: PKC)
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCB
  entrez: '5579'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: PKC)
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCE
  entrez: '5581'
- word: (RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: PLD
  symbol: PLD
  source: bioentities_symbol
  hgnc_symbol: PLD6
  entrez: '201164'
- word: PLA2
  symbol: PLA2
  source: bioentities_symbol
  hgnc_symbol: PLA2G4D
  entrez: '283748'
- word: PLA2
  symbol: PLA2
  source: bioentities_symbol
  hgnc_symbol: PLA2G2E
  entrez: '30814'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL13
  entrez: '10563'
- word: PLD
  symbol: PLD
  source: bioentities_symbol
  hgnc_symbol: PLD5
  entrez: '200150'
- word: PI(3)K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: PKC)
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCA
  entrez: '5578'
- word: FYN
  symbol: FYN
  source: hgnc_symbol
  hgnc_symbol: FYN
  entrez: '2534'
- word: NF-KB
  symbol: NF-kappaB
  source: hgnc_alias_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: PKC)
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCD
  entrez: '5580'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL12
  entrez: '6387'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PI(3)K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: BTK)
  symbol: BTK
  source: hgnc_symbol
  hgnc_symbol: BTK
  entrez: '695'
- word: PI(3)K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI(3)K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL5
  entrez: '6374'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: (RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: (SYK
  symbol: SYK
  source: hgnc_symbol
  hgnc_symbol: SYK
  entrez: '6850'
- word: PI(3)K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL10
  entrez: '3627'
- word: PI(3)K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: SPHK1
  symbol: SPHK1
  source: hgnc_symbol
  hgnc_symbol: SPHK1
  entrez: '8877'
- word: PI(3)K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: SHIP1
  symbol: SHIP1
  source: hgnc_alias_symbol
  hgnc_symbol: INPP5D
  entrez: '3635'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL14
  entrez: '9547'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: PI(3)K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: (RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
chemicals:
- word: amines
  source: MESH
  identifier: D000588
- word: Prostaglandins
  source: MESH
  identifier: D011453
- word: Sphingosine
  source: MESH
  identifier: D013110
- word: Leukotrienes
  source: MESH
  identifier: D015289
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
